Genetic Leap is leading the next giant leap in human healthcare with AI technologies for precise gene control through RNA-targeted molecules that are potent, safe, convenient, and reversible. The company has multiple promising drug programs (oncology, immunology, neuro) at pre-IND stage and has experience collaborating with Pharma (Astellas Pharma, IDTdna)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2017 (2021 for RNA-targeted small molecules focus)
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Direct MYC-targeted, orally available small molecule cancer drug
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
